Current Colorectal Cancer Reports

, Volume 5, Issue 1, pp 3–4

Rofecoxib and cardiovascular adverse effects: New insights

  • Sarab Kraus
  • Nadir Arber
Clinical Trials Report

References

  1. 1.
    Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Nissen SE: Adverse cardiovascular effects of rofecoxib. N Engl J Med 2006, 355:203–204.PubMedCrossRefGoogle Scholar
  3. 3.
    Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895.PubMedCrossRefGoogle Scholar
  4. 4.
    Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873–884.PubMedCrossRefGoogle Scholar
  5. 5.
    Jones R, Rubin G, Berenbaum F, Scheiman J: Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008, 121:464–474.PubMedCrossRefGoogle Scholar
  6. 6.
    McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633–1644.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Sarab Kraus
  • Nadir Arber

There are no affiliations available

Personalised recommendations